Trial reportJMIR research protocols2026
Efficacy of Liuzijue in Improving Respiratory Muscle Dysfunction in Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Trial.
Trial report in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a prevalent chronic lung disease, and respiratory muscle dysfunction is one of its key pathogenic mechanisms. Liuzijue, a traditional Chinese health exercise, has been widely applied in COPD rehabilitation, showing benefits in improving pulmonary function and quality of life. However, clinical evidence regarding its specific effects on respiratory muscle function remains insufficient. Objective: This study describes the protocol of a randomized controlled trial designed to evaluate the effects of Liuzijue exercise on respiratory muscle function and functional outcomes in patients with COPD. Methods: This study adopts a randomized controlled trial design, with participants randomly assigned to either a control group or a Liuzijue group. The control group receives standardized pharmacological treatment, while the Liuzijue group receives the same pharmacological treatment combined with Liuzijue intervention. The coprimary outcome measures are the 6-minute walk test and surface electromyography of the respiratory muscles. Secondary outcome measures include pulmonary function tests and respiratory questionnaires. Exploratory outcome measures include isokinetic strength testing of the core muscle groups and kinematic analysis. Results: As of manuscript submission, this trial has received ethical approval (reference number: CHEC2025-149) and secured funding in May 2024. Participant recruitment began on August 1, 2025, and has enrolled 15 participants in the control group and 8 participants in the Liuzijue group to date. Recruitment is expected to be completed by September 2026, followed by data collection until December 2026, with data analysis planned for January 2027 and the final results expected to be prepared and submitted for publication in spring 2027. Conclusions: This study is one of the first rigorously designed clinical trials to investigate the effects of Liuzijue on improving respiratory muscle function in patients with COPD, aiming to provide reliable clinical evidence for its efficacy in the rehabilitation of respiratory muscle function in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.